<DOC>
	<DOC>NCT01156025</DOC>
	<brief_summary>The study objective is to evaluate the efficacy and the safety of GV 550 in comparison to placebo in patients with acute adenoviral keratoconjuncivitis.</brief_summary>
	<brief_title>Efficacy and Safety of GV 550 in Acute Adenovirus Keratoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis</mesh_term>
	<criteria>Written informed consent Male or female aged from 18 to 80 years old Acute adenoviral keratoconjunctivitis Active ocular allergy Ocular herp√®s disease History of bacterial conjunctivitis / blepharoconjunctivitis within the last month before the inclusion visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>GV550</keyword>
	<keyword>Acute adenoviral keratoconjunctivitis</keyword>
</DOC>